AN2 Therapeutics Reports Phase 1b Data for Oral Epetraborole
/PRNewswire/ -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious...
Source: prnewswire.com
Page 6 - Eric Easom News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Eric Easom. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Eric Easom Today - Breaking & Trending Today
AN2 Therapeutics Provides Regulatory Update and Plan to Initiate Clinical Development for Epetraborole Targeting NTM Lung Disease
/PRNewswire/ -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious...
Source: prnewswire.com
AN2 Therapeutics Nets $80 million for Novel Lung Disease Program
California-based AN2 Therapeutics secured $80 million in Series B funding round to help advance its novel nontuberculous mycobacterial lung disease program.
Source: biospace.com
AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program
/PRNewswire/ -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious...
Source: prnewswire.com
AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program
/PRNewswire/ -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious...
Source: prnewswire.com